Valeant Pharmaceuticals International Inc., of Laval, Quebec, closed a registered offering of common shares in which it raised gross proceeds of about $1.45 billion to fund its acquisition of Salix Pharmaceuticals Ltd., of Raleigh, N.C., as well as repayments of indebtedness of Salix and certain transaction expenses.